Skip to main content

Table 2 Baseline characteristics of all patients

From: Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study

 

Younger sitters (n = 107)

Older sitters (n = 73)

Lost sitters (n = 37)

Lost walkers (n = 39)

Age at symptom onset (months)

10.5 ± 5.9

11.3 ± 5.1

10.0 ± 4.4

23.8 ± 16.1

Age at start of treatment (months)

30.8 ± 13.2

120.9 ± 39.1

98.5 ± 61.6

134.7 ± 54.6

SMN2 copy number

    

  1 SMN2

0 (0%)

1 (1.4%)

0 (0%)

0 (0%)

  2 SMN2

11 (10.3%)

5 (6.8%)

2 (5.4%)

0 (0%)

  3 SMN2

78 (72.9%)

37 (50.7%)

23 (62.2%)

26 (66.7%)

  ≥ 4 SMN2

12 (11.2)

11 (15.1%)

3 (8.1%)

6 (15.4%)

Unknown

6 (5.6%)

19 (26.0%)

9 (24.3%)

7 (17.9%)

HFMSE score (n)

20.7 ± 11.4 (52)

15.7 ± 12.4 (47)

13.7 ± 14.4 (15)

25.9 ± 9.1 (33)

RULM score (n)

16.2 ± 7.1 (26)

19.0 ± 7.5 (51)

12.8 ± 7.1 (18)

26.0 ± 6.1 (29)

Sitting without support

100%

100%

0%

89.7%

Non-invasive ventilator support

12 (11.2%)

16 (21.9%)

9 (24.3%)

2 (5.1%)

Tube feeding

4 (3.7%)

5 (6.8%)

5 (13.5%)

0 (0%)

Scoliosis

30 (28.0%)

62 (85.0%)

26 (70.3%)

29 (74.4%)

Contractures

1 (0.9%)

13 (17.8%)

9 (24.3%)

7 (17.9%)

  1. Data are listed as mean ± standard deviation or n (%)